Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management.
Rewan Gamal MohamedRania SaberMohamed Ali HusseinAmira ShalabyNouran YasserSherif KamalLobna ShalabyMohamed NagyPublished in: Personalized medicine (2024)
Aim: Vancomycin, a crucial treatment for Gram-positive bacteria, necessitates therapeutic drug monitoring (TDM) to prevent treatment failures. We investigated the healthcare professional's compliance toward TDM of vancomycin recommendations and follow-up levels. Materials & methods: We collected data from 485 patients who received vancomycin in the Children's Cancer Hospital Egypt 57357 medical records system (Cerner) over 4 months, from January to April 2020. Results: Our data shows that only 54% of patients had TDM requests from healthcare professionals for the total patients who received vancomycin treatment. The healthcare professionals' compliance with the recommendations was 91.7%, while the follow-up levels were 66.7%. Conclusion: While overall adherence to recommendations is strong, enhancing compliance with follow-up levels remains a priority for improvement.
Keyphrases
- healthcare
- methicillin resistant staphylococcus aureus
- electronic health record
- palliative care
- end stage renal disease
- ejection fraction
- clinical practice
- squamous cell carcinoma
- emergency department
- machine learning
- metabolic syndrome
- adipose tissue
- mass spectrometry
- insulin resistance
- peritoneal dialysis
- weight loss
- lymph node metastasis
- single molecule
- patient reported outcomes
- atomic force microscopy